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Abstract
Objective: The objective of this EBM review is to determine whether or not the use of
mesalamine decreases abdominal pain in adults with IBS.
Study Design: Review of 3 randomized control trials.
Data Sources: All articles were published in English between 2012 and 2016. Articles were
obtained from peer-reviewed journals using PubMed.
Outcomes: The outcome measured was the level or presence of abdominal and was measured
via binary scale, 10-point visual analogue scale rated by patients on a 0 to 10 scale with 0 being
no pain and 10 being the maximum level of pain and via patient symptom diary questionnaire.
Results: Barbara et al. showed that mesalazine reduced abdominal pain and discomfort superior
to placebo in patients with IBS, but this was not statistically significant, with a p-value of 0.404.
Tuteja et al. showed that mesalamine was superior to placebo at reducing abdominal pain from
baseline in patients with post-infective IBS, but this was not statistically significant, with a pvalue of 0.83. Lam et al. showed that mesalazine did not decrease abdominal pain in patients
with IBS-D superior to placebo, with a p-value of 0.83.
Conclusions: All three articles used mesalazine to treat abdominal pain and used placebo as the
control group. Although two articles showed that mesalamine can decrease abdominal pain at a
superior level to placebo, the results we not clinically significant. The third trial showed that
mesalamine was not superior to placebo in decreasing abdominal pain. Further studies and
perhaps larger studies are needed to determine if mesalamine can have a statistically significant
impact on decreasing abdominal pain.
Keywords: IBS, mesalamine, abdominal pain, inflammation
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INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder
characterized by abdominal pain with disorder in defecation and stool consistency in the absence
of another cause for these symptoms.1 It is the most common function bowel disorder and can be
encountered in a variety of practice settings.2 Physicians as well as physician assistants may
encounter the disorder in the settings in which they work. It is diagnosed based on the Rome IV
criteria which states that abdominal pain must be present at least once a day for at least three
months and must include two or more of the following criteria: related to defecation, change in
the appearance of the stool, or change in the frequency of the stool. There are two main types of
IBS, IBS-D, which is diarrhea predominant and IBS-C, which is constipation predominant.
Patients may also suffer from a combination of both which is categorized as mixed with
alternating diarrhea and constipation. Symptoms of the disorder include bloating, diarrhea,
constipation, excessive flatulence, and abdominal pain.1 Abdominal pain and discomfort are
hallmark symptoms of the disorder and are usually one of the symptoms that drive patients to
seek medical attention.2
The disorder is associated with comorbid conditions including psychiatric conditions
such as anxiety and depression, and visceral hypersensitivity.3 There has also been shown to be a
genetic link to the disorder, with patients who have a family history being predisposed to
developing IBS at some point in their lifetime.2 Despite these associations the pathophysiology if
IBS is still poorly understood and mainly considered to be idiopathic.4
The symptoms patients with IBS experience can have an immense impact on their quality
of life. An article in Expert Opin estimated that in 2015 the US lost $205 million in productivity
due to IBS.5 IBS has a marked impact on the healthcare system as well. The total cost of
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healthcare visits in the US for IBS was estimated by Aran Ediciones to be $20,000,000 yearly in
2016 which includes the cost of laboratory and diagnostic studies needed to rule out other
conditions.6 IBS is the reason for greater than 3.5. million office visits each year in the US.6
IBS is traditionally treated with pharmacological and non-pharmacological treatment
methods. Non-pharmacological treatments include psychotherapy, exercise, and diet
modification which includes avoiding triggers e.g., FODMAP diet, increasing fiber intake, and
addressing lactose intolerance.4 Pharmacotherapy is targeted at symptomatic treatment.
Antispasmodic agents such as dicyclomine and hyoscyamine are used to ease abdominal pain
and decrease visceral hypersensitivity. Peppermint oil capsules are also used as an antispasmodic
agent. Low dose tri-cyclic antidepressants and SSRIs are also used for treating abdominal pain as
well as other symptoms.4 For IBS-C lubiprostone and linaclotide are used to treat constipation by
increasing serotonin levels, aiding in bowel movement regularity. Bulking agents such as
psyllium and osmotic laxatives such as polyethylene glycol are used to attract water to the lumen
of the colon aiding in stool passage. For IBS-D loperamide and diphenoxylate atropine are used
as antidiarrheals. In rare cases antibiotics may also be used if the onset of IBS is after an acute
case of gastroenteritis. These cases are deemed as post-infective IBS.1
Mesalamine also known as mesalazine is a topical salicylate that is used as a treatment
for ulcerative colitis to decrease bowel inflammation. It has been previously found that patients
with IBS can exhibit low levels of inflammation in bowel mucosa especially after acute cases of
gastroenteritits.2 According to a study published in the British Medical Journal up to 36.8% of
subjects developed IBS following recovery from acute infectious gastroenteritis, suggesting the
possibility that IBS has an inflammatory etiology.2 Other factors can also contribute to this lowgrade inflammation including stress, atopy, genetics, and various other factors.2 Since it has
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already been demonstrated that patients with IBS can have low levels of inflammation in GI
mucosa including inflammatory markers and immune cells and a study has been previously
demonstrated that mesalamine decreased inflammatory markers and immune cells in the bowel
mucosa of patients with IBS intuitively using the anti-inflammatory mesalamine to treat the
symptoms of the disorder may be the solution to treating the underlying cause of IBS instead of
simply treating the disorder symptomatically.2
OBJECTIVE
The objective of this selective EBM review is to determine whether or not mesalamine
decreases abdominal pain in patients with IBS when compared to placebo.
METHODS
The studies used in this review were found by searching PubMed using the keywords
“irritable bowel syndrome” and “mesalamine”. The studies selected for this review fit the
clinical topic selected and the results measured were Patient-Oriented Evidence that Matters
(POEMs). The studies selected consisted of randomized control human trials published after
2009. All other studies including non-human studies were excluded. Table 1 presents inclusion
and exclusion criteria for each individual study. After review of criteria, 3 studies were selected
for this review. All of the studies were written in English and were obtained from a peerreviewed journals.
The population studied were adults, 18 years and older. The intervention used was
mesalamine. The comparison group for each study was placebo. Each study used various doses
of the drug. Barbara et al. used 800 mg of mesalazine three times daily for 12 weeks, Tuteja et
al. used 1.6 g of mesalamine twice daily for 12 weeks, and lastly Lam et al. used 2 g of
mesalazine daily for one week then twice daily for 11 weeks. The outcome measured from all
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three studies was the subjective decrease in abdominal pain intensity. Pain intensity was
measured using a binary scale in Barbara et al. and a scale of 0 to 10 for Lam et al. In the Tuteja
et al. study, participants rated their abdominal pain as none, minimal, mild, moderate, or severe.
Statistical significance of each study’s results was reported as p-values.
OUTCOMES MEASURED
Outcome measured for all 3 studies was the participants’ subjective decrease in
abdominal pain. Outcomes from the different studies were measured via 10-point visual analogue
scale labeled 0 to 10 with 0 being no pain and 10 being the maximum level of pain. One study
also used patient symptom diary questionnaire where the participant was asked their level of pain
and rated it as none, minimal, mild, moderate or severe.1
RESULTS
Barbara et al. (2016) performed a randomized control trial comparing the use of 800 mg
of oral mesalazine to placebo. The population for this study were adults 18-65 with a diagnosis
of any IBS subtype and was mostly made up of Caucasian females.2 The participants were
recruited from 21 Italian centers.2 The full inclusion and exclusion criteria for this study can be
found in Table 1. One-hundred and eighty patients were randomized and 88 were assigned to the
mesalazine, while 92 were assigned to placebo.2 The allocation of patients to each treatment
group was concealed from those enrolling subjects and well as the subjects in the study.2 Patients
received mesalazine or placebo three times daily over the 12-week period based on their assigned
treatment group. Patients visited the study center every 2 weeks during the treatment period and
their abdominal pain was assessed by their answer to the question “did you have satisfactory
relief of your abdominal discomfort or pain during the last week?”.2 Patients were considered
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responders if they gave an affirmative answer to the question for more than 75% of the treatment
period.2
Table 1. Demographics and Characteristics of Included Studies
Study
Tuteja1
(2012)

Type
RCT

#Pts
20

Age(yrs)
18-75yrs

Inclusion Criteria
Age 18-75, male or
female, history of
new onset of IBS
following acute
gastroenteritis,
presence of
symptoms for more
than 3 months,
normal gross
appearance of the
colonic mucosa on
endoscopy,
negative tests

Exclusion Criteria
previous diagnosis of or
history compatible with
IBS prior to acute
gastroenteritis, clinically
significant cardiac,
pulmonary, hepatic or
renal disorder, chronic
gastrointestinal (GI)
disorder, allergy to aspirin
or mesalamine, current
pregnancy

W/D
3

Intervention
Mesalamine
1.6 g bid for
12 weeks

Lam7
(2016)

RCT

136

18-75yrs

Age 18-75, normal
coloscopy with
biopsy results,
normal blood
count, serum
calcium and
albumin, CRP, and
negative celiac
serology, no lactose
intolerance,
negative pregnancy
test

Any positive screening
tests, Prior history of
major abdominal surgery,
liver or kidney
impairment, or chronic
ingestion of any antiinflammatory drugs or
medications that can
affect gut motility.
Patients on unstable dose
of SSRIs and TCAs for
less than 3 months

115

2 g of
mesalazine qd
for 1 week
then bid for
11 weeks

1

RCT

180

18-65yrs

18-65yrs, patients
with Rome III
criteria for
diagnosis of IBS

Pregnant, breastfeeding,
not using reliable
contraception, NSAID
use, corticosteroid use,
mast cell stabilizers, the
use of topic or systemic
antibiotics in the last
month, treatment with
lactulose or with any
compound that lowered
the colonic pH and could
prevent the release of the
active moiety, major
abdominal surgery, a
history of inflammatory
bowel disease or
diverticular disease

57

Mesalazine
800mg tid for
12 weeks

Joanis, Mesalazine to Decrease Abdom Pain

6

According to the study 57 patients withdrew from the study prior to completion due to
withdrawal of consent (14), adverse events (14), protocol violations (6), lost to follow-up (8),
and other reasons (5).2 Dropouts that were due to inefficacy were treated as non-responders,
while all other reasons were considered responders and missing data was ignored. 2 Worst-case
analysis and best-case analysis led to similar conclusions.2 Due to this result the study concluded
that the missing data had no effect on the end conclusion.2 The study included 172 patients in the
intention to treat analysis, 86 in each treatment group.2 Twenty-eight patients in the mesalazine
group were designated responders while 23 in the placebo group were designated responders.2
The Number Needed to Treat (NNT) to achieve the treatment affect was 17. Although the results
showed a greater number of responders in the mesalazine treatment group over placebo at 5.9%,
the p-value was 0.404, which is not statistically significant, not less than or equal to 0.05.2 Table
2 depicts the mean change from baseline of abdominal pain and discomfort for both treatment
groups.
Table 2. Descriptive Statistics by Treatment Group for Abdominal Pain/Discomfort Intensity2
Mesalazine (n=86)

Placebo (n=86)

Mean (SD)

Baseline (week 2)

4.59 (2.54)

4.50 (2.34)

Mean change versus

End of treatment

-1.07 (2.54)

-1.21 (2.36)

baseline (SD)

Tuteja et al. performed a randomised control trial comparing the use mesalamine 1.6 g
orally twice daily for 12 weeks to placebo in decreasing abdominal pain in patients with postinfective IBS.1 Blinding was achieved for this study.1 The population for this study were adults
18-75 years of age with diagnosed IBS after an acute case of gastroenteritis.1 Fifteen of the
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participants were returned missionaries or international travelers who developed IBS after acute
gastroenteritis while abroad.1 Further inclusion and exclusion criteria are listed in Table 1.
Twenty patients were randomized and 10 were allocated to each treatment group, mesalamine
and placebo.1 Three patients withdrew from the study before completion.1 Two from the
mesalamine treatment group and one from placebo.1 The results from these patients were
excluded.1 Level of pain was recorded for 7 days at baseline and then every 4 weeks.1 The mean
change from baseline is recorded in Table 3.
Table 3. Mean Change in Abdominal Pain from Baseline per Treatment Group after 12 Weeks of
Therapy with 95% CI1
Treatment

p-value = 0.83

Mesalamine

1.5

Placebo

-1.1

The mean change from baseline was superior with use of mesalamine when compared to
placebo.1 However, these results were not statistically significant since the p-value was 0.83.1
Lam et al. performed a 12-week randomized control trial evaluating the decrease in
abdominal pain in patients with IBS-D when treated with mesalamine 2 g twice daily compared
to placebo.7 Participants and those enrolling participants were blinded to allocation of treatment
group.7 The population for this study consisted of patients 18-75 with diagnosed IBS-D.7 Other
inclusion and exclusion criteria are listed in Table 1. One-hundred and thirty-six patients were
randomized and 68 were assigned to each treatment group.7 Twenty-one patients’ results were
not analyzed and were considered dropouts.7 Reasons for dropouts included withdrawal of
consent, loss to follow up, and adverse events.7 This resulted in 57 patients in the mesalazine
treatment group and 58 in the placebo control group.7 Daily pain levels were recorded by patients
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in a daily symptom diary.7 At the end of treatment, weeks 11 and 12, the mean pain score was
taken and can be seen in Table 4. The table shows that the end of trial difference between groups
was -0.6 in favor of placebo, with a p-value of 0.83.7 This showed that mesalazine was not
superior to placebo at decreasing abdominal pain in patients with IBS-D.7
Table 4. Mean Abdominal Pain Score per Treatment Group at Weeks 11-12 (95% CI)7
Treatment group
mesalazine
placebo

P= 0.83
2.8
2.2

DISCUSSION
IBS is the most common functional bowel disorder encountered in provider practice, but
the disorder pathophysiology is not clearly understood. Current treatment consists of treating
whatever symptoms may arise without knowing the underlying cause to prevent symptoms from
occurring. Inflammation is believed to play a role in the pathophysiology of IBS especially after
cases of acute gastroenteritis.1,2,7 Mesalazine is used in ulcerative colitis to decrease
prostaglandins, which in turn decreases inflammation and symptoms associated with the
disease.1 Physicians, physician assistants and other practitioners already prescribe mesalazine for
this purpose so its safety of use to an extent has already been established. The link between
inflammation and IBS could be the key to treating the underlying cause of symptoms and
decreasing them, namely abdominal pain.
Only two of the three studies discussed in this review showed a superior decrease in
abdominal pain with use of mesalamine when compared to placebo. Even so, these results were
not statistically significant. One limitation to these studies are the study populations. The study
done by Tuteja et al. did not specify the ethnicity of its subjects, which could play a role in
determining if mesalazine is more effective at decreasing abdominal pain in certain ethnicities
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when compared to others.1 The study also consisted of missionary travelers who’s IBS started
after an acute case of gastroenteritis which is not completely generalizable to the entire
population of IBS patients.1 Also it would be helpful for mean ages to be provided instead of
simply the age range for the inclusion criteria and the median age. This would help to specify
further what population has been target by the study. Another issue with the population is that is
consisted of 11 men and 6 women, who were not evenly distributed across treatment groups.1
The difference in the two treatment groups could affect the results of the study. The population
for this study was also quite small with only 17 participants.1 A larger study population would
certainly be beneficial. Lastly the pharmacist was not blinded to the assigning of participants.
This could certainly have affected the outcome of the study.1
The population for the study done by Lam et al. consisted predominantly of middle-aged
females, but the allocation was evenly distributed among the two treatment groups.7 Extended
demographics for these participants would also have been helpful towards analyzing the
treatment effect on that specific population. The study population for the study performed by
Barbara et al. consists of a majority of middle-aged Caucasian females. Although this study is
highly specific to that population, it is not generalizable to the population as a whole.
Another issue that can be foreseen with all 3 studies is that they were outpatient trials
where patients were not supervised for the entirety of the study.1,2,7 The results were dependent
on the patient’s compliance with the study protocol, but there was no mention of a method
ensuring patients adhered to the study protocol. The method of assessing the level of pain also
had the potential to skew results as in Barbara et al.2 It is more standardized to use a 10-point
visual analog scale that does not sway patients to a specific response based on the words used to
describe the level of pain.
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An additional issue that arose in the Barbara et al. study is that there was a large number
of dropouts in the study. Patients who did not complete the entire 12-week treatment were
considered as having a major protocol violation.2 Also the study states that all dropouts due to
inefficacy were considered non-responders while all other dropouts were considered responders
and the missing data was ignored.2 This could have a significant impact in the outcome of the
study. Lastly both Barbara et al and Lam et al allowed the used of medications traditionally used
to treat IBS during the course of the study.2,7 Discontinuing traditional treatments prior to and
during the duration of the entire study may demonstrate the clarity of the effect of mesalamine of
abdominal pain in patients with IBS.
CONCLUSIONS
Based on the three studies discussed in this review mesalamine does not decrease
abdominal pain in adults with IBS superior to placebo. Two of the studies show showed a
superior decrease in abdominal with use of mesalamine when compared to placebo, while one
demonstrated that mesalamine was not superior to placebo, but the results were not statistically
significant and did not give the confidence that these results were not simply due to chance.1,2,7
Issues arose in these studies including the protocols used, the adherence of patients to these
protocols, and other variables that were present that could skew the outcomes of the studies.
Larger studies are needed to assess the effect that mesalamine therapy has in reducing abdominal
pain in patients with IBS. It would also be important to limit the number of confounding
variables to determine the true treatment effect of mesalamine on abdominal pain. Lastly it
would be beneficial for patients to participate in an inpatient study where they could be observed
and outside variables would be limited.
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